Marvel withdraws biosimilar insulins as EU bioequivalence rules evolve
This article was originally published in Scrip
Executive Summary
Marvel BioSciences has hit another hitch in its efforts to get its biosimilar insulin onto the EU market, after it withdrew approval applications for three products that were under evaluation by the European Medicines Agency.